Prostatype Genomics (Sweden) Market Value
| PROGEN Stock | SEK 1.26 0.01 0.80% |
| Symbol | Prostatype |
Prostatype Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prostatype Genomics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prostatype Genomics.
| 01/23/2025 |
| 01/18/2026 |
If you would invest 0.00 in Prostatype Genomics on January 23, 2025 and sell it all today you would earn a total of 0.00 from holding Prostatype Genomics AB or generate 0.0% return on investment in Prostatype Genomics over 360 days. Prostatype Genomics is related to or competes with Qlife Holding, Aino Health, Fluicell, 2cureX AB, Chordate Medical, and Stayble Therapeutics. Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests More
Prostatype Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prostatype Genomics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prostatype Genomics AB upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.25 | |||
| Information Ratio | 0.1084 | |||
| Maximum Drawdown | 74.84 | |||
| Value At Risk | (10.71) | |||
| Potential Upside | 24.32 |
Prostatype Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prostatype Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prostatype Genomics' standard deviation. In reality, there are many statistical measures that can use Prostatype Genomics historical prices to predict the future Prostatype Genomics' volatility.| Risk Adjusted Performance | 0.0899 | |||
| Jensen Alpha | 1.38 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | 0.1558 | |||
| Treynor Ratio | 0.9299 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prostatype Genomics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Prostatype Genomics Backtested Returns
Prostatype Genomics is out of control given 3 months investment horizon. Prostatype Genomics maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to break down and interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.82% are justified by taking the suggested risk. Use Prostatype Genomics Risk Adjusted Performance of 0.0899, coefficient of variation of 862.11, and Semi Deviation of 7.95 to evaluate company specific risk that cannot be diversified away. Prostatype Genomics holds a performance score of 10 on a scale of zero to a hundred. The company holds a Beta of 1.65, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prostatype Genomics will likely underperform. Use Prostatype Genomics accumulation distribution, day typical price, as well as the relationship between the semi variance and maximum drawdown , to analyze future returns on Prostatype Genomics.
Auto-correlation | 0.62 |
Good predictability
Prostatype Genomics AB has good predictability. Overlapping area represents the amount of predictability between Prostatype Genomics time series from 23rd of January 2025 to 22nd of July 2025 and 22nd of July 2025 to 18th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prostatype Genomics price movement. The serial correlation of 0.62 indicates that roughly 62.0% of current Prostatype Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.62 | |
| Spearman Rank Test | 0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Prostatype Genomics lagged returns against current returns
Autocorrelation, which is Prostatype Genomics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Prostatype Genomics' stock expected returns. We can calculate the autocorrelation of Prostatype Genomics returns to help us make a trade decision. For example, suppose you find that Prostatype Genomics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Prostatype Genomics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Prostatype Genomics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Prostatype Genomics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Prostatype Genomics stock over time.
Current vs Lagged Prices |
| Timeline |
Prostatype Genomics Lagged Returns
When evaluating Prostatype Genomics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Prostatype Genomics stock have on its future price. Prostatype Genomics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Prostatype Genomics autocorrelation shows the relationship between Prostatype Genomics stock current value and its past values and can show if there is a momentum factor associated with investing in Prostatype Genomics AB.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.